MX2015012905A - Formulaciones de factor viii recombinantes. - Google Patents
Formulaciones de factor viii recombinantes.Info
- Publication number
- MX2015012905A MX2015012905A MX2015012905A MX2015012905A MX2015012905A MX 2015012905 A MX2015012905 A MX 2015012905A MX 2015012905 A MX2015012905 A MX 2015012905A MX 2015012905 A MX2015012905 A MX 2015012905A MX 2015012905 A MX2015012905 A MX 2015012905A
- Authority
- MX
- Mexico
- Prior art keywords
- factor viii
- recombinant factor
- viii formulations
- formulations
- polymer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
Abstract
Se proporcionan formulaciones líquidas y liofilizadas de factor VIII recombinante que incluyen formulaciones para FVIII conjugado con polímero, tal como factor VIII PEGilado.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361799495P | 2013-03-15 | 2013-03-15 | |
US201361869191P | 2013-08-23 | 2013-08-23 | |
PCT/US2014/023357 WO2014150477A1 (en) | 2013-03-15 | 2014-03-11 | Recombinant factor viii formulations |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2015012905A true MX2015012905A (es) | 2016-06-16 |
Family
ID=51580768
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015012905A MX2015012905A (es) | 2013-03-15 | 2014-03-11 | Formulaciones de factor viii recombinantes. |
Country Status (17)
Country | Link |
---|---|
US (1) | US20160030524A1 (es) |
EP (1) | EP2970430A4 (es) |
JP (1) | JP2016518321A (es) |
KR (1) | KR20150132449A (es) |
CN (1) | CN105209487A (es) |
AU (1) | AU2014237111B2 (es) |
BR (1) | BR112015022730A2 (es) |
CA (1) | CA2905739A1 (es) |
HK (1) | HK1213273A1 (es) |
MX (1) | MX2015012905A (es) |
PE (1) | PE20160121A1 (es) |
RU (1) | RU2015144076A (es) |
SG (2) | SG10201803999UA (es) |
TW (1) | TW201521761A (es) |
UY (1) | UY35412A (es) |
WO (1) | WO2014150477A1 (es) |
ZA (1) | ZA201507684B (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3247400A1 (en) * | 2015-01-18 | 2017-11-29 | Biogen MA Inc. | Formulations and screening of biological therapeutic agents |
EA202190827A1 (ru) | 2015-11-13 | 2021-11-30 | Баксалта Инкорпорейтед | Вирусные векторы, кодирующие рекомбинантные варианты fviii с повышенной экспрессией для генной терапии гемофилии a |
TW202039546A (zh) | 2019-01-16 | 2020-11-01 | 美商巴克斯歐塔公司 | 用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體 |
EP4013389A1 (en) * | 2019-08-16 | 2022-06-22 | Octapharma AG | Stabilizing buffer for factor viii and vwf |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5763401A (en) * | 1996-07-12 | 1998-06-09 | Bayer Corporation | Stabilized albumin-free recombinant factor VIII preparation having a low sugar content |
CN1339170A (zh) * | 1999-02-01 | 2002-03-06 | 日本电气硝子株式会社 | 阴极射线管及其制造方法 |
CN100553678C (zh) * | 1999-02-22 | 2009-10-28 | 巴克斯特国际有限公司 | 新的无白蛋白的因子ⅷ制剂 |
US7205278B2 (en) * | 2001-06-14 | 2007-04-17 | The Scripps Research Institute | Stabilized proteins with engineered disulfide bonds |
GB0207092D0 (en) * | 2002-03-26 | 2002-05-08 | Sod Conseils Rech Applic | Stable pharmaceutical composition containing factor VIII |
PL1824988T3 (pl) * | 2004-11-12 | 2018-01-31 | Bayer Healthcare Llc | Ukierunkowana na miejsce modyfikacja czynnika VIII |
KR20080108147A (ko) * | 2006-03-31 | 2008-12-11 | 백스터 인터내셔널 인코포레이티드 | 페질화된 인자 viii |
JP5779780B2 (ja) * | 2008-11-07 | 2015-09-16 | バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated | 第viii因子製剤 |
US20120121613A1 (en) * | 2009-01-19 | 2012-05-17 | Bayer Healthcare Llc | Protein conjugate having an endopeptidase- cleavable bioprotective moiety |
-
2014
- 2014-03-11 AU AU2014237111A patent/AU2014237111B2/en not_active Ceased
- 2014-03-11 JP JP2016501214A patent/JP2016518321A/ja active Pending
- 2014-03-11 RU RU2015144076A patent/RU2015144076A/ru not_active Application Discontinuation
- 2014-03-11 MX MX2015012905A patent/MX2015012905A/es unknown
- 2014-03-11 BR BR112015022730A patent/BR112015022730A2/pt not_active IP Right Cessation
- 2014-03-11 SG SG10201803999UA patent/SG10201803999UA/en unknown
- 2014-03-11 WO PCT/US2014/023357 patent/WO2014150477A1/en active Application Filing
- 2014-03-11 PE PE2015002012A patent/PE20160121A1/es not_active Application Discontinuation
- 2014-03-11 SG SG11201507618YA patent/SG11201507618YA/en unknown
- 2014-03-11 CN CN201480025467.XA patent/CN105209487A/zh active Pending
- 2014-03-11 CA CA2905739A patent/CA2905739A1/en not_active Abandoned
- 2014-03-11 KR KR1020157029441A patent/KR20150132449A/ko not_active Application Discontinuation
- 2014-03-11 US US14/774,191 patent/US20160030524A1/en not_active Abandoned
- 2014-03-11 EP EP14770228.6A patent/EP2970430A4/en not_active Withdrawn
- 2014-03-13 TW TW103109012A patent/TW201521761A/zh unknown
- 2014-03-13 UY UY0001035412A patent/UY35412A/es not_active Application Discontinuation
-
2015
- 2015-10-14 ZA ZA2015/07684A patent/ZA201507684B/en unknown
-
2016
- 2016-02-04 HK HK16101334.5A patent/HK1213273A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
JP2016518321A (ja) | 2016-06-23 |
CA2905739A1 (en) | 2014-09-25 |
ZA201507684B (en) | 2017-06-28 |
KR20150132449A (ko) | 2015-11-25 |
US20160030524A1 (en) | 2016-02-04 |
HK1213273A1 (zh) | 2016-06-30 |
EP2970430A1 (en) | 2016-01-20 |
SG10201803999UA (en) | 2018-06-28 |
BR112015022730A2 (pt) | 2017-10-31 |
UY35412A (es) | 2014-10-31 |
WO2014150477A1 (en) | 2014-09-25 |
TW201521761A (zh) | 2015-06-16 |
AU2014237111B2 (en) | 2018-06-21 |
RU2015144076A (ru) | 2017-04-24 |
AU2014237111A1 (en) | 2015-10-08 |
EP2970430A4 (en) | 2017-01-11 |
PE20160121A1 (es) | 2016-03-03 |
SG11201507618YA (en) | 2015-10-29 |
CN105209487A (zh) | 2015-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA202101142B (en) | Methods and compositions comprising purified recombinant polypeptides | |
HRP20190454T1 (hr) | Rekombinantni faktor viii proteini | |
PH12016500316A1 (en) | Improved adenovirus formulations | |
MX2016007063A (es) | Peptidos terapeuticos. | |
CY1117214T1 (el) | Συνθεση για ελεγχομενη διεγερση των ωοθηκων | |
MX2013015168A (es) | Co-agonista del receptor de glucagon/glp-1. | |
MX2013015176A (es) | Co-agonistas del receptor de glucagon/glp-1. | |
SG11201505924TA (en) | Factor viii polypeptide formulations | |
EP3033098A4 (en) | Recombinant factor viii proteins | |
TR201905787T4 (tr) | Liyofilize TAT-NR2B9C formülasyonu. | |
WO2013123046A3 (en) | Cathode buffer materials and related devices and methods | |
MX2015012905A (es) | Formulaciones de factor viii recombinantes. | |
EP3052526A4 (en) | Recombinant polypeptides comprising mhc class ii 1 domains | |
HK1223374A1 (zh) | 抗體或其用途 | |
MX349487B (es) | Composiciones de higiene bucal. | |
UA90689U (uk) | Комплексний протипаразитарний препарат "лактоверм" | |
AR095431A1 (es) | Formulaciones de fviii recombinante | |
ES2426017A2 (es) | Microemulsión que comprende colagenasa y usos | |
JO3497B1 (ar) | مستحضر صيدلي يشتمل على hcg مأشوب | |
TH1101001042B (th) | รีคอมบิเเนนท์เวคเตอร์ซึ่งประกอบด้วยยีนที่เข้ารหัสฮิวเเมน กลูโคไคเนส |